Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
By Jean-Pierre Issa, G. Garcia-Manero, F. Giles, Rajan Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C. Rosenfeld, J. Cortes and 1 more. Blood, 2004
825 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/2a964b425de84c970925bd325d16620255c631a9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Targeting FTO suppresses cancer stem cell maintenance and immune evasion (2020, positive): “HMAs are wildly used for the treatment of patients with AML or myelodysplastic syndrome (MDS), especially in elderly patients and in those who are not eligible for allogeneic stem cell transplantation (Dombret et al., 2015; Issa et al., 2004; Yun et al., 2016).”
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, neutral): “Median number of courses (range) 5 (1-18) 8 (1-17) 9 (1-15)”
- Decitabine improves patient outcomes in myelodysplastic syndromes (2006, neutral): “001 CR 8 (9) 0 PR 7 (8) 0 Clinical improvement Overall Improvement (CR PR HI) 27 (30) 6 (7) .”
- Epigenetic Determinants of Cancer. (2016, background): “agents have now found application in the treatment of certain hematological malignancies, particularly myelodysplastic syndrome, which is a preleukemic condition occurring mainly in elderly patients (Lubbert 2000; Wijermans et al. 2000; Silverman et al. 2002; Issa et al. 2004).”
- Epigenetics in human disease and prospects for epigenetic therapy (2004, background): “Exciting new clinical trials have shown that low doses of these agents might be efficacious in treating myeloid dysplastic syndrome and other leukaemia”
- Cancer epigenetics. (2005, background): “First, insight into the mode of action, the mechanism of toxicity and the pharmacokinetics of decitabine inspired an improved protocol with prolonged administration at lower doses, with equal, if not better efficacy than previous regimens (55).”
- Transient Low Doses of DNA Demethylating Agents Exert Durable Anti-tumor Effects on Hematological and Epithelial Tumor Cells (2012, background): “Remarkably, the improved clinical efficacy and safety profile have emerged only as doses of the drugs, given either alone (Issa et al., 2004; Kantarjian et al., 2006, 2007) or in combination with histone deacetylase (HDAC) inhibitors (Gore et al.”